Lamina-specific abnormalities of AMPA receptor trafficking and signaling molecule transcripts in the prefrontal cortex in schizophrenia - PubMed (original) (raw)
. 2006 Dec 15;60(8):585-98.
doi: 10.1002/syn.20329.
Affiliations
- PMID: 16983646
- DOI: 10.1002/syn.20329
Lamina-specific abnormalities of AMPA receptor trafficking and signaling molecule transcripts in the prefrontal cortex in schizophrenia
Monica Beneyto et al. Synapse. 2006.
Abstract
Ampakines, positive AMPA receptor modulators, can improve cognitive function in schizophrenia, and enhancement of AMPA receptor-mediated currents by them potentiates the activity of antipsychotics. In vitro studies have revealed that trafficking of AMPA receptors is mediated by specific interactions of a complex network of proteins that also target and anchor them at the postsynaptic density (PSD). The aim of this study was to determine whether there are abnormalities of the molecules associated with trafficking and localization of AMPA receptors at the PSD in the dorsolateral prefrontal cortex (DLPFC) in schizophrenia. We analyzed AMPA receptor expression in DLPFC in schizophrenia, major depression, bipolar disorder, and a control group, by examining transcript levels of all four AMPA receptor subunits by in situ hybridization. We found decreased GluR2 subunit expression in all three illnesses, decreased GluR3 in major depression, and decreased GluR4 in schizophrenia. However, autoradiography experiments showed no changes in AMPA receptor binding; thus, we hypothesized that these changes in receptor subunit stoichiometry do not alter binding to the assembled receptor, but rather intracellular processing. In situ hybridization for AMPA-trafficking molecules showed decreased expression of PICK1 and increased expression of stargazin in DLPFC in schizophrenia, both restricted to large cells of cortical layer III. These data suggest that AMPA-mediated glutamatergic neurotransmission is compromised in schizophrenia, particularly at the level of AMPA-related PSD proteins that mediate AMPA receptor trafficking, synaptic surface expression, and intracellular signaling.
Similar articles
- mRNA expression of AMPA receptors and AMPA receptor binding proteins in the cerebral cortex of elderly schizophrenics.
Dracheva S, McGurk SR, Haroutunian V. Dracheva S, et al. J Neurosci Res. 2005 Mar 15;79(6):868-78. doi: 10.1002/jnr.20423. J Neurosci Res. 2005. PMID: 15696539 - Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder.
Beneyto M, Meador-Woodruff JH. Beneyto M, et al. Neuropsychopharmacology. 2008 Aug;33(9):2175-86. doi: 10.1038/sj.npp.1301604. Epub 2007 Nov 21. Neuropsychopharmacology. 2008. PMID: 18033238 - A novel action of stargazin as an enhancer of AMPA receptor activity.
Yamazaki M, Ohno-Shosaku T, Fukaya M, Kano M, Watanabe M, Sakimura K. Yamazaki M, et al. Neurosci Res. 2004 Dec;50(4):369-74. doi: 10.1016/j.neures.2004.10.002. Neurosci Res. 2004. PMID: 15567474 - Regulation of AMPA receptors and synaptic plasticity.
Santos SD, Carvalho AL, Caldeira MV, Duarte CB. Santos SD, et al. Neuroscience. 2009 Jan 12;158(1):105-25. doi: 10.1016/j.neuroscience.2008.02.037. Epub 2008 Feb 29. Neuroscience. 2009. PMID: 18424006 Review. - Functional modulation of AMPA receptors by transmembrane AMPA receptor regulatory proteins.
Sager C, Tapken D, Kott S, Hollmann M. Sager C, et al. Neuroscience. 2009 Jan 12;158(1):45-54. doi: 10.1016/j.neuroscience.2007.12.046. Epub 2008 Jan 18. Neuroscience. 2009. PMID: 18304745 Review.
Cited by
- Prefrontal cortical alterations of glutamate and GABA neurotransmission in schizophrenia: Insights for rational biomarker development.
Schoonover KE, Dienel SJ, Lewis DA. Schoonover KE, et al. Biomark Neuropsychiatry. 2020 Dec;3:100015. doi: 10.1016/j.bionps.2020.100015. Epub 2020 May 18. Biomark Neuropsychiatry. 2020. PMID: 32656540 Free PMC article. - Glutamate receptor abnormalities in schizophrenia: implications for innovative treatments.
Rubio MD, Drummond JB, Meador-Woodruff JH. Rubio MD, et al. Biomol Ther (Seoul). 2012 Jan;20(1):1-18. doi: 10.4062/biomolther.2012.20.1.001. Biomol Ther (Seoul). 2012. PMID: 24116269 Free PMC article. Review. - Transcriptional profile of pyramidal neurons in chronic schizophrenia reveals lamina-specific dysfunction of neuronal immunity.
Wu X, Shukla R, Alganem K, Zhang X, Eby HM, Devine EA, Depasquale E, Reigle J, Simmons M, Hahn MK, Au-Yeung C, Asgariroozbehani R, Hahn CG, Haroutunian V, Meller J, Meador-Woodruff J, McCullumsmith RE. Wu X, et al. Mol Psychiatry. 2021 Dec;26(12):7699-7708. doi: 10.1038/s41380-021-01205-y. Epub 2021 Jul 16. Mol Psychiatry. 2021. PMID: 34272489 Free PMC article. - Mapping the Consequences of Impaired Synaptic Plasticity in Schizophrenia through Development: An Integrative Model for Diverse Clinical Features.
Forsyth JK, Lewis DA. Forsyth JK, et al. Trends Cogn Sci. 2017 Oct;21(10):760-778. doi: 10.1016/j.tics.2017.06.006. Epub 2017 Jul 25. Trends Cogn Sci. 2017. PMID: 28754595 Free PMC article. Review. - Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.
Sanacora G, Zarate CA, Krystal JH, Manji HK. Sanacora G, et al. Nat Rev Drug Discov. 2008 May;7(5):426-37. doi: 10.1038/nrd2462. Nat Rev Drug Discov. 2008. PMID: 18425072 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical